Matthew Matasar, MD, discusses odronextamab and the ongoing phase 1 ELM-1 trial in patients with CD20-positive B-cell malignancies.

Odronextamab demonstrated a manageable safety profile and generated durable responses in patients with R/R DLBCL who have ...

The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...

The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...

The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

Video content above is prompted by the following: Thanks to all of you for this rich and informative discussion. Before we conclude, I’d like to get final thoughts from each of you.

It contains one Ig-like (immunoglobulin-like) domain and one ITAM domain. CD3E, along with CD3-gamma, CD3-delta, CD3-zeta, and T-cell receptor (TCR) alpha/beta or gamma/delta heterodimers ...

driven by the expanded labels of Eylea HD and Libtayo and by the potential launches of Ordspono (odronextamab), linvoseltamab, itepekimab, pozelimab/cemdisiran, and the novel oncology combination ...

The company is advancing several promising R&D programs, including pivotal data expected for Linvoseltamab in multiple myeloma and odronextamab in follicular lymphoma. Regeneron Pharmaceuticals ...